Semin Liver Dis 2021; 41(02): 136-141
DOI: 10.1055/s-0040-1722646
Review Article

Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?

Pedro Luiz Serrano Uson Junior
1  Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona
2  Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota
3  Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona
,
Bolni Marius Nagalo
1  Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona
2  Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota
3  Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona
4  Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota
,
Daniel H. Ahn
1  Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona
,
Tanios Bekaii-Saab
1  Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona
,
Mitesh J. Borad
1  Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona
2  Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota
3  Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona
4  Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota
› Author Affiliations

Abstract

The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.



Publication History

Publication Date:
06 May 2021 (online)

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA